Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) gapped up prior to trading on Monday after Morgan Stanley raised their price target on the stock from $30.00 to $43.00. The stock had previously closed at $21.19, but opened at $23.06. Morgan Stanley currently has an overweight rating on the stock. Taysha Gene Therapies shares last traded at $25.38, with a volume of 1,012 shares changing hands.
Several other research analysts also recently commented on TSHA. William Blair assumed coverage on Taysha Gene Therapies in a research report on Monday, March 1st. They issued an “outperform” rating and a $46.00 price target on the stock. Oppenheimer assumed coverage on Taysha Gene Therapies in a report on Monday, January 4th. They set an “outperform” rating and a $42.00 price objective on the stock. Chardan Capital lifted their price objective on Taysha Gene Therapies from $60.00 to $67.50 and gave the stock a “buy” rating in a report on Monday. Finally, Zacks Investment Research lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, March 9th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $43.92.
A number of hedge funds have recently made changes to their positions in TSHA. Citigroup Inc. acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at $43,000. Strs Ohio acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at $55,000. New York State Common Retirement Fund acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at $130,000. Point72 Hong Kong Ltd acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at $132,000. Finally, American International Group Inc. acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at $134,000. 42.19% of the stock is currently owned by institutional investors and hedge funds.
Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, March 2nd. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.68). On average, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -3.19 EPS for the current year.
Taysha Gene Therapies Company Profile (NASDAQ:TSHA)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.
See Also: Understanding Market Liquidity
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.